A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects
- Registration Number
- NCT04730050
- Lead Sponsor
- LG Chem
- Brief Summary
To assess the safety, tolerability and pharmacokinetic characteristics of TT-01025 in healthy male subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 64
-
Written informed consent must be obtained before any assessment is performed.
-
Age ≥ 18 years and ≤ 55 years, male or female.
-
Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weighs at least 50 kg.
-
No clinically significant findings in medical examination, including physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory tests.
-
Male participant and his female spouse/partner who is of childbearing potential agree to use highly effective contraception* consisting of two forms of birth control (at least one of which must be a barrier method) from signing of informed consent throughout the study period and for 90 days after final study drug administration.
-
A female subject of childbearing potential who is sexually active agrees to use highly effective contraception* consisting of two forms of birth control (at least one of which must be a barrier method) from signing of informed consent throughout the duration of the study period and for 90 days after last study drug administration. If the next menstrual period is delayed, a pregnancy test will be required for exclusion of pregnancy.
-
Highly effective contraception is defined as:
- Established use of oral, injected, or implanted hormonal methods of contraception
- Placement of an intrauterine device or intrauterine system
- Barrier methods of contraception: condom with spermicidal foam, gel, film, cream, suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, or suppository
-
-
Able to understand and sign informed consent and to comply with the protocol
- Any history of clinically serious disease.
- Any active or unstable clinically significant medical condition as judged by the investigator.
- Subject has abnormal Screening findings or Day -2 laboratory value that suggest a clinically significant underlying disease.
- Hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes.
- Received any investigational drug within 30 days or 5x T1/2 whichever is longer before the Screening.
- Participants who have undergone major surgery ≤ 2 months prior to start study drug.
- Impaired cardiac function including clinically significant arrhythmias or clinically significant abnormality in clinical test, including but not limited to any of the following at Screening and
Check-in, repeat testing is allowed for verification, at the discretion of the Investigator:
-
Heart rate < 45 beats per minute (bpm) or > 90 bpm (taken during blood pressure measurement).
-
Systolic blood pressure (SBP) < 90 mmHg or > 140 mmHg; diastolic blood pressure (DBP) < 50 mmHg or > 90 mmHg.
-
Average of the 3 QT intervals corrected using Fridericia's formula (QTcF) > 450 milliseconds.
-
Second degree or higher Atrioventricular block on ECG
-
Estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2
- Impaired renal function or abnormal liver enzymes at baseline, including but not limited to:
-
Alanine aminotransferase (ALT) > upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) > ULN
-
Estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73m2
- Women who are pregnant or lactating, or intending to become pregnant before, during or within 90 days after exit from this study.
- Women with baseline FSH ≥40mIU/ml
- Participant who has had a loss of more than 100 mL blood (e.g., a blood donation) within 2 months before study drug administration, or has received any blood, plasma, or platelet transfusions within 3 months before Check-in, or plans to donate blood, ova or sperm during the study or within 3 months after the study.
- Participant who has a known history of, or a positive test result for, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) types 1 or 2 at screening.
- Participant who has used prescription or over-the-counter (OTC) medication (other than ≤2 g/day paracetamol [acetaminophen] or ≤800 mg/day ibuprofen), vitamins, or herbal remedies, within 7 days or 5 half-lives before study drug administration, whichever is longer.
- Participant who has a history of alcohol abuse (defined as an alcohol intake more than 21 units per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine, or 20 mL of spirits.
- Participant who smokes cigarettes or uses other nicotine-containing products (e.g., vape, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers), has done so in the 3 months prior to screening.
- Consumption of caffeine or xanthine-containing food or beverages from at least 72 hours prior to Check-in to the clinical research unit until at least 24 hours after last drug administration
- Participant who has a positive test for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, MDMA, oxycodone, phencyclidine, methamphetamine, tricyclic antidepressants, opiates, methadone, cocaine, cannabinoids, amphetamines, or cotinine) at Screening or Check-in.
- Subject is unable to complete this study for other reasons or the Investigator believes that he or she should be excluded.
- Participant who has a positive swab test of COVID-19 from Screening or Check-in testing.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Drug: TT-01025-CL TT-01025-CL TT-01025-CL Drug: Placebo TT-01025-CL Placebo of TT-01025-CL
- Primary Outcome Measures
Name Time Method Adverse Events 30 days
- Secondary Outcome Measures
Name Time Method Terminal half-life up to 7 days post-dose Cmax up to 7 days post-dose AUC up to 7 days post-dose
Trial Locations
- Locations (1)
Las Vegas Clinical Research Unit
🇺🇸Las Vegas, Nevada, United States